{
     "PMID": "27234917",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20180123",
     "LR": "20180123",
     "IS": "1873-7862 (Electronic) 0924-977X (Linking)",
     "VI": "26",
     "IP": "8",
     "DP": "2016 Aug",
     "TI": "L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo.",
     "PG": "1297-309",
     "LID": "10.1016/j.euroneuro.2016.05.004 [doi] S0924-977X(16)30045-1 [pii]",
     "AB": "The control of the secretory activity of serotonergic neurons has been pointed out to reduce motor and non-motor side effects of the antiparkinsonian drug L-DOPA. This strategy deserves further investigation because it is presently unclear whether L-DOPA promotes a non-vesicular release of dopamine and serotonin from serotonergic neurons. To get a full neurochemical picture compatible with the existence of such a mechanism, we combined multisite intracerebral microdialysis, post mortem tissue measurement and single unit extracellular recordings in the dorsal raphe nucleus from hemiparkinsonian rats. L-DOPA (3-100mg/kg, ip.) non-homogeneously decreased extracellular serotonin levels in the striatum, substantia nigra pars reticulata, hippocampus and prefrontal cortex and homogenously serotonin tissue content in the striatum, cortex and cerebellum. L-DOPA (12mg/kg) did not modify the firing rate or pattern of serotonergic-like neurons recorded in the dorsal raphe nucleus. When focusing on serotonin release in the prefrontal cortex and the hippocampus, we found that L-DOPA (12 or 100mg/kg) enhanced serotonin extracellular levels in both regions upon Ca(2+) removal. Concomitantly, L-DOPA-stimulated dopamine release partly persisted in the absence of Ca(2+) in a region-dependent manner. Local application of the serotonin reuptake inhibitor citalopram (1microM) blunted the responses to L-DOPA (3-12mg/kg), measured as extracellular dopamine levels, most prominently in the hippocampus. These data stress that L-DOPA, already at low to moderate doses, promotes non-vesicular releases of serotonin and dopamine in a region-dependent manner.",
     "CI": [
          "Copyright (c) 2016 Elsevier B.V. and ECNP. All rights reserved."
     ],
     "FAU": [
          "Miguelez, Cristina",
          "Navailles, Sylvia",
          "Delaville, Claire",
          "Marquis, Loise",
          "Lagiere, Melanie",
          "Benazzouz, Abdelhamid",
          "Ugedo, Luisa",
          "De Deurwaerdere, Philippe"
     ],
     "AU": [
          "Miguelez C",
          "Navailles S",
          "Delaville C",
          "Marquis L",
          "Lagiere M",
          "Benazzouz A",
          "Ugedo L",
          "De Deurwaerdere P"
     ],
     "AD": "Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain; Department of Pharmacology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain. Universite de Bordeaux, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France. Universite de Bordeaux, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France. Universite de Bordeaux, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France. Universite de Bordeaux, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France. Universite de Bordeaux, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France. Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain. Universite de Bordeaux, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodegeneratives, UMR 5293, F-33000 Bordeaux, France. Electronic address: deurwaer@u-bordeaux2.fr.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "DEP": "20160524",
     "PL": "Netherlands",
     "TA": "Eur Neuropsychopharmacol",
     "JT": "European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology",
     "JID": "9111390",
     "RN": [
          "0 (Antiparkinson Agents)",
          "0 (Cholestanols)",
          "0 (Dopamine Agents)",
          "0 (Serotonin Uptake Inhibitors)",
          "0 (microdiplane)",
          "0DHU5B8D6V (Citalopram)",
          "333DO1RDJY (Serotonin)",
          "46627O600J (Levodopa)",
          "54-16-0 (Hydroxyindoleacetic Acid)"
     ],
     "SB": "IM",
     "MH": [
          "Action Potentials/drug effects",
          "Animals",
          "Antiparkinson Agents/administration & dosage/pharmacology/*therapeutic use",
          "Cholestanols",
          "Citalopram/pharmacology",
          "*Disease Models, Animal",
          "Dopamine Agents/administration & dosage/pharmacology/therapeutic use",
          "Dopaminergic Neurons/*drug effects/secretion",
          "Dose-Response Relationship, Drug",
          "Hippocampus/drug effects/physiopathology/secretion",
          "Hydroxyindoleacetic Acid/metabolism",
          "Levodopa/administration & dosage/pharmacology/secretion/*therapeutic use",
          "Male",
          "Organ Specificity",
          "Parkinson Disease/*drug therapy/physiopathology",
          "Prefrontal Cortex/drug effects/physiopathology/secretion",
          "Rats, Sprague-Dawley",
          "Serotonergic Neurons/*drug effects/secretion",
          "Serotonin/*secretion",
          "Serotonin Uptake Inhibitors/pharmacology",
          "Single-Cell Analysis",
          "Synaptic Transmission/drug effects"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "*Electrophysiology",
          "*Exocytosis",
          "*Hippocampus",
          "*Intracerebral microdialysis",
          "*Prefrontal cortex",
          "*Tissue measurement"
     ],
     "EDAT": "2016/05/29 06:00",
     "MHDA": "2018/01/24 06:00",
     "CRDT": [
          "2016/05/29 06:00"
     ],
     "PHST": [
          "2016/02/17 00:00 [received]",
          "2016/04/20 00:00 [revised]",
          "2016/05/08 00:00 [accepted]",
          "2016/05/29 06:00 [entrez]",
          "2016/05/29 06:00 [pubmed]",
          "2018/01/24 06:00 [medline]"
     ],
     "AID": [
          "S0924-977X(16)30045-1 [pii]",
          "10.1016/j.euroneuro.2016.05.004 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Eur Neuropsychopharmacol. 2016 Aug;26(8):1297-309. doi: 10.1016/j.euroneuro.2016.05.004. Epub 2016 May 24.",
     "term": "hippocampus"
}